Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,387.00DKK
10:59am EDT
Change (% chg)

kr.5.00 (+0.36%)
Prev Close
kr.1,382.00
Open
kr.1,382.00
Day's High
kr.1,389.00
Day's Low
kr.1,375.00
Volume
183,975
Avg. Vol
307,986
52-wk High
kr.1,489.00
52-wk Low
kr.970.00

Latest Key Developments (Source: Significant Developments)

Genmab Q1 oper profit DKK 46 million; above expectations
Wednesday, 10 May 2017 11:03am EDT 

May 10 (Reuters) - GENMAB :Q1 USD 255 MILLION IN NET SALES OF DARZALEX® (DARATUMUMAB); RESULTING IN ROYALTY INCOME OF DKK 211 MILLION.GENMAB - USD 255 MILLION IN NET SALES OF DARZALEX IN Q1.Q1 REVENUE DKK 251 MILLION (REUTERS POLL DKK 263 MILLION).GENMAB - IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017..Q1 OPERATING PROFIT DKK 46 MILLION (REUTERS POLL DKK 24.7 MILLION).  Full Article

Genmab announces new late stage combination study of Daratumumab in multiple myeloma
Friday, 28 Apr 2017 09:26am EDT 

April 28 (Reuters) - Genmab A/S ::Genmab announces new phase III combination study of Daratumumab in multiple myeloma.Study is expected to start in Q2 2017 and is designed to confirm results from MMY1001 study.Prescription drug user fee act date of June 17, 2017 for Daratumumab.Janssen Research with European myeloma network plans to start phase III study of Daratumumab in relapsed and refractory multiple myeloma.  Full Article

Genmab announces European Marketing Authorization for Darzalex
Friday, 28 Apr 2017 06:26am EDT 

April 28 (Reuters) - GENMAB :GENMAB ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR DARZALEX® (DARATUMUMAB) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SAYS GENMAB WILL RECEIVE MILESTONE PAYMENTS TOTALING USD 48 MILLION FROM JANSSEN BIOTECH, INC.SAYS THESE MILESTONE PAYMENTS WERE INCLUDED IN FINANCIAL GUIDANCE ISSUED BY GENMAB ON FEBRUARY 22, 2017 AND THEREFORE THERE IS NO CHANGE TO COMPANY'S FINANCIAL GUIDANCE FOLLOWING THIS APPROVAL.  Full Article

Genmab Q1 net sales of Darzalex at $255 million
Tuesday, 18 Apr 2017 06:55am EDT 

April 18 (Reuters) - GENMAB A/S GEN.CO:GENMAB ANNOUNCES NET SALES OF DARZALEX®(DARATUMUMAB) FOR FIRST QUARTER OF 2017<<>>.NET SALES OF DARZALEX IN Q1 OF 2017 TOTALED $255 MILLION.SAYS WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.  Full Article

BRIEF-Genmab A/S says Phase II study in NHL will not proceed
Friday, 31 Mar 2017 02:02am EDT 

Genmab A/S : Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial . Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed . Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned . Genmab says announcement has no impact on other ongoing or planned studies with daratumumab . Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab . Study will not proceed to stage 2 based on results of a data review . Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds .In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment.  Full Article

Genmab A/S says Phase II study in NHL will not proceed
Thursday, 30 Mar 2017 12:29pm EDT 

Genmab A/S : Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial . Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed . Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned . Genmab says announcement has no impact on other ongoing or planned studies with daratumumab . Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab . Study will not proceed to stage 2 based on results of a data review . Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds .In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment.  Full Article

EMA recommends approval of Daiichi Sankyo's anticoagulant
Friday, 24 Feb 2017 07:00am EST 

EU Medicines Agency: EU medicines Agency recommendations for February 2017 . EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban . EU Medicines Agency says adopted positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex . EU Medicines Agency recommends approval of Hospira UK Limited's Pemetrexed for treatment of non-small cell lung cancer Source (http://bit.ly/2lCHPks) Further company coverage: [4568.T] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Genmab FY operating income up to DKK 1,053 million
Wednesday, 22 Feb 2017 11:01am EST 

Genmab A/S : Revenue was 1,816 million Danish crowns ($257.45 million) in 2016 compared to 1,133 million crowns in 2015 . Operating income was 1,053 million crowns in 2016 compared to 730 million crowns in 2015 . Sees 2017 revenue of 1,950 million crowns - 2,150 million crowns . Sees 2017 operating income of 900 million - 1,100 million crowns .Projected revenue for 2017 consists primarily of DARZALEX royalties of 930 million – 1,100 million crowns that are based on an estimated $1,100 million – $1,300 million of DARZALEX net sales in 2017 and DARZALEX milestones of 800 million crowns.  Full Article

Genmab raises 2016 financial guidance
Monday, 6 Feb 2017 12:39am EST 

Genmab A/S : Raises its 2016 financial guidance published on Dec. 20, 2016 . Expects FY revenue of 1.79 billion Danish crowns - 1.84 billion Danish crowns ($259.43 million-$266.67 million) against previous guidance of 1.72 billion-1.77 billion crowns . Expects FY operating income of 1.02 billion crowns - 1.07 billion crowns against previous guidance of 895 million-945 million crowns .Says revenue range increased primarily due to higher royalties on net sales of DARZALEX by Janssen and achievement of additional DuoBody milestones.  Full Article

Genmab: net sales of Darzalex in 2016 $572 million
Tuesday, 24 Jan 2017 06:52am EST 

Genmab A/S : Net sales of Darzalex in 2016 totaled $572 million .Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc..  Full Article

More From Around the Web

BRIEF-Genmab announces plans for new studies of Daratumumab

* Genmab says 3 new phase iii studies of daratumumab planned in multiple myeloma and amyloidosis